Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

Alcon logo

Alcon

Status and phase

Terminated
Phase 3

Conditions

Macular Degeneration

Treatments

Drug: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL

Study type

Interventional

Funder types

Industry

Identifiers

NCT00065728
C-03-15

Details and patient eligibility

About

The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.

Enrollment

111 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Patients with subfoveal exudative age-related macular degeneration (AMD) who were previously enrolled in long-term studies with anecortave acetate. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

111 participants in 1 patient group

Anecortave Acetate, 15 mg
Experimental group
Description:
One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
Treatment:
Drug: Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems